US6448369B1
(en)
*
|
1997-11-06 |
2002-09-10 |
Shearwater Corporation |
Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
|
US7642323B2
(en)
|
1997-11-06 |
2010-01-05 |
Nektar Therapeutics |
Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
|
SG2008070138A
(en)
|
1998-10-16 |
2017-08-30 |
Biogen Ma Inc |
Polymer conjugates of interferon beta- 1a and their uses
|
IL142350A0
(en)
|
1998-10-16 |
2002-03-10 |
Biogen Inc |
Interferon-beta fusion proteins and pharmaceutical compositions containing the same
|
EP1259562B1
(de)
*
|
1999-12-22 |
2006-02-15 |
Nektar Therapeutics Al, Corporation |
Sterisch gehinderte derivate von wasserlöslichen polymeren
|
AU2001238595A1
(en)
*
|
2000-02-22 |
2001-09-03 |
Shearwater Corporation |
N-maleimidyl polymer derivatives
|
US7053150B2
(en)
*
|
2000-12-18 |
2006-05-30 |
Nektar Therapeutics Al, Corporation |
Segmented polymers and their conjugates
|
PT1436012T
(pt)
|
2001-10-18 |
2018-03-27 |
Nektar Therapeutics |
Conjugados poliméricos de antagonistas de opióides
|
ES2566797T3
(es)
|
2002-01-18 |
2016-04-15 |
Biogen Ma Inc. |
Compuestos de polímero de polialquileno y usos de éstos
|
KR100608415B1
(ko)
*
|
2002-07-24 |
2006-08-02 |
에프. 호프만-라 로슈 아게 |
폴리알킬렌 글리콜산 첨가제
|
AP2005003246A0
(en)
*
|
2002-09-09 |
2005-03-31 |
Nektar Therapeutics Al Corp |
Water-soluble polymer alkanals
|
ATE412684T1
(de)
|
2002-09-09 |
2008-11-15 |
Nektar Therapeutics Al Corp |
Verfahren zur herstellung von wasserlöslichen polymerderivaten mit terminalen carboxylgruppen
|
US20050221443A1
(en)
*
|
2003-01-06 |
2005-10-06 |
Xencor, Inc. |
Tumor necrosis factor super family agonists
|
US7553930B2
(en)
*
|
2003-01-06 |
2009-06-30 |
Xencor, Inc. |
BAFF variants and methods thereof
|
US20060014248A1
(en)
*
|
2003-01-06 |
2006-01-19 |
Xencor, Inc. |
TNF super family members with altered immunogenicity
|
US20050130892A1
(en)
*
|
2003-03-07 |
2005-06-16 |
Xencor, Inc. |
BAFF variants and methods thereof
|
DE602004024041D1
(de)
|
2003-03-05 |
2009-12-24 |
Halozyme Inc |
Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen
|
US20090123367A1
(en)
*
|
2003-03-05 |
2009-05-14 |
Delfmems |
Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
*
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US7642340B2
(en)
|
2003-03-31 |
2010-01-05 |
Xencor, Inc. |
PEGylated TNF-α variant proteins
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
CA2520875A1
(en)
*
|
2003-03-31 |
2004-10-21 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
US20040260034A1
(en)
|
2003-06-19 |
2004-12-23 |
Haile William Alston |
Water-dispersible fibers and fibrous articles
|
US7892993B2
(en)
|
2003-06-19 |
2011-02-22 |
Eastman Chemical Company |
Water-dispersible and multicomponent fibers from sulfopolyesters
|
US8513147B2
(en)
|
2003-06-19 |
2013-08-20 |
Eastman Chemical Company |
Nonwovens produced from multicomponent fibers
|
US7482376B2
(en)
*
|
2003-07-03 |
2009-01-27 |
3-Dimensional Pharmaceuticals, Inc. |
Conjugated complement cascade inhibitors
|
WO2005006963A2
(en)
|
2003-07-18 |
2005-01-27 |
Broncus Technologies, Inc. |
Devices for maintaining patency of surgically created channels in tissue
|
US8394365B2
(en)
|
2003-09-17 |
2013-03-12 |
Nektar Therapeutics |
Multi-arm polymer prodrugs
|
CA2537336C
(en)
*
|
2003-09-17 |
2013-02-26 |
Nektar Therapeutics Al, Corporation |
Multi-arm polymer prodrugs
|
WO2005035564A2
(en)
|
2003-10-10 |
2005-04-21 |
Xencor, Inc. |
Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
|
EP2905033B1
(de)
*
|
2003-12-16 |
2020-09-02 |
Nektar Therapeutics |
Monodisperse PEGylierte Naloxol-enthaltende Zusammensetzungen
|
US20060182692A1
(en)
*
|
2003-12-16 |
2006-08-17 |
Fishburn C S |
Chemically modified small molecules
|
EP1711825A4
(de)
*
|
2004-01-07 |
2008-01-23 |
Ambit Biosciences Corp |
Konjugierte kleine moleküle
|
KR101178744B1
(ko)
*
|
2004-01-21 |
2012-09-07 |
넥타르 테라퓨틱스 |
프로피온산-말단 중합체의 제조 방법
|
CN103755800B
(zh)
*
|
2004-02-02 |
2016-02-24 |
Ambrx公司 |
经修饰的人类生长激素多肽与其用途
|
US20070265200A1
(en)
*
|
2004-03-17 |
2007-11-15 |
Eli Lilly And Company |
Glycol Linked Fgf-21 Compounds
|
WO2005115477A2
(en)
*
|
2004-04-13 |
2005-12-08 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
CN102603895B
(zh)
|
2004-06-18 |
2016-09-28 |
Ambrx公司 |
新颖抗原结合多肽和其用途
|
JP2008506703A
(ja)
|
2004-07-14 |
2008-03-06 |
ユニバーシティ オブ ユタ リサーチ ファウンデーション |
ネトリン関連化合物および用途
|
AU2005327906B2
(en)
*
|
2004-07-21 |
2010-05-13 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
EP2502941A1
(de)
*
|
2004-10-25 |
2012-09-26 |
Intezyne Technologies Inc. |
Heterobifunktionelles Poly(ethylenglykol) und seine Verwendungen
|
US8058291B2
(en)
|
2005-04-06 |
2011-11-15 |
Adamas Pharmaceuticals, Inc. |
Methods and compositions for the treatment of CNS-related conditions
|
US7619007B2
(en)
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
SG160437A1
(en)
|
2004-12-22 |
2010-04-29 |
Ambrx Inc |
Modified human growth hormone
|
US7816320B2
(en)
|
2004-12-22 |
2010-10-19 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
|
JP2008525032A
(ja)
|
2004-12-22 |
2008-07-17 |
アンブレツクス・インコーポレイテツド |
組換えヒト成長ホルモンを発現及び精製するための方法
|
AU2005319518B2
(en)
*
|
2004-12-22 |
2010-09-09 |
Ambrx, Inc. |
Compositions of aminoacyl-tRNA synthetase and uses thereof
|
US7714114B2
(en)
*
|
2005-02-16 |
2010-05-11 |
Nektar Therapeutics |
Conjugates of an EPO moiety and a polymer
|
US20060233740A1
(en)
*
|
2005-03-23 |
2006-10-19 |
Bossard Mary J |
Conjugates of an hGH moiety and a polymer
|
DE602006017202D1
(de)
|
2005-05-13 |
2010-11-11 |
Lilly Co Eli |
Pegylierte glp-1-verbindungen
|
EP1885404A2
(de)
*
|
2005-06-01 |
2008-02-13 |
Alza Corporation |
Biokonjugationsreaktionen für acylierende polyethylenglykol reagentien
|
CA2609205A1
(en)
|
2005-06-03 |
2006-12-14 |
Ambrx, Inc. |
Improved human interferon molecules and their uses
|
EP1951890A4
(de)
|
2005-11-16 |
2009-06-24 |
Ambrx Inc |
Verfahren und zusammensetzungen mit nichtnatürlichen aminosäuren
|
NZ568578A
(en)
*
|
2005-12-14 |
2011-10-28 |
Ambrx Inc |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
US7462627B2
(en)
*
|
2006-02-09 |
2008-12-09 |
Enzon Pharmaceuticals, Inc. |
Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
|
US7671067B2
(en)
*
|
2006-02-09 |
2010-03-02 |
Enzon Pharmaceuticals, Inc. |
Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
|
AU2007233116B2
(en)
*
|
2006-03-30 |
2013-05-09 |
Palatin Technologies, Inc. |
Cyclic natriuretic peptide constructs
|
EP2004633A4
(de)
*
|
2006-03-30 |
2009-08-26 |
Palatin Technologies Inc |
Lineare natriuretische peptidkonstrukte
|
US8580746B2
(en)
*
|
2006-03-30 |
2013-11-12 |
Palatin Technologies, Inc. |
Amide linkage cyclic natriuretic peptide constructs
|
WO2007117685A2
(en)
|
2006-04-07 |
2007-10-18 |
Nektar Therapeutics Al, Corporation |
Conjugates of an anti-tnf-alpha antibody
|
WO2007124461A2
(en)
|
2006-04-20 |
2007-11-01 |
Amgen Inc. |
Glp-1 compounds
|
EP2010477A4
(de)
*
|
2006-04-27 |
2012-05-30 |
Intezyne Technologies Inc |
Poly (ethylenglykol) mit chemisch ungleichen endgruppen
|
WO2007149594A2
(en)
|
2006-06-23 |
2007-12-27 |
Quintessence Biosciences, Inc. |
Modified ribonucleases
|
JP2009543868A
(ja)
|
2006-07-17 |
2009-12-10 |
クインテセンス バイオサイエンシーズ インコーポレーティッド |
癌治療に関する方法および組成物
|
WO2008030558A2
(en)
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and their uses
|
NZ574960A
(en)
|
2006-09-08 |
2012-02-24 |
Ambrx Inc |
Suppressor trna transcription in vertebrate cells
|
PT2061878E
(pt)
|
2006-09-08 |
2014-04-22 |
Ambrx Inc |
Supressor híbrido arnt para células de vertebrados
|
US8354549B2
(en)
*
|
2006-11-30 |
2013-01-15 |
Nektar Therapeutics |
Method for preparing a polymer conjugate
|
SI2842967T1
(sl)
|
2007-01-18 |
2017-01-31 |
Eli Lilly And Company |
Pegilirani amiloid beta fab
|
RU2009133793A
(ru)
*
|
2007-02-09 |
2011-03-20 |
Энзон Фармасьютикалз, Инк. (Us) |
Лечение резистентных или невосприимчивых форм рака конъюгатами 7-этил-10-гидроксикампотецина с множеством ответвлений цепи
|
CA2682147C
(en)
|
2007-03-30 |
2017-08-08 |
Ambrx, Inc. |
Modified fgf-21 polypeptides and their uses
|
BRPI0810622A2
(pt)
|
2007-05-02 |
2020-10-13 |
Ambrx, Inc. |
polipeptídeos de interferon beta modificados e seus usos
|
KR100979462B1
(ko)
|
2007-08-03 |
2010-09-02 |
한국화학연구원 |
안트라사이클라인계 항암약물 봉입용 리포솜 및 이의제조방법
|
CA2702043A1
(en)
*
|
2007-10-08 |
2009-04-16 |
Quintessence Biosciences, Inc. |
Compositions and methods for ribonuclease-based therapies
|
JP5547083B2
(ja)
|
2007-11-20 |
2014-07-09 |
アンブルックス,インコーポレイテッド |
修飾されたインスリンポリペプチドおよびそれらの使用
|
MX2010008632A
(es)
|
2008-02-08 |
2010-08-30 |
Ambrx Inc |
Leptina-polipeptidos modificados y sus usos.
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
WO2009128917A2
(en)
|
2008-04-14 |
2009-10-22 |
Halozyme, Inc. |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
NZ591235A
(en)
|
2008-07-23 |
2012-07-27 |
Ambrx Inc |
Modified bovine g-csf polypeptides comprising non natural amino acid and their uses treating infections such as mastitis
|
CN102159250B
(zh)
*
|
2008-08-11 |
2014-08-06 |
尼克塔治疗公司 |
多臂的聚合烷酸酯偶联物
|
EP2328619B1
(de)
*
|
2008-08-22 |
2016-12-07 |
Baxalta GmbH |
Polymere benzyl-carbonat-derivate
|
TW201010732A
(en)
*
|
2008-08-29 |
2010-03-16 |
Enzon Pharmaceuticals Inc |
Method of treating RAS associated cancer
|
EP2331139B1
(de)
*
|
2008-09-11 |
2019-04-17 |
Nektar Therapeutics |
Polymer-alpha-hydroxy-aldehyd und keton-reagenzien und konjugationsverfahren
|
WO2010042145A1
(en)
*
|
2008-09-19 |
2010-04-15 |
Nektar Therapeutics |
Polymer conjugates of glp-2-like peptides
|
WO2010033222A2
(en)
*
|
2008-09-19 |
2010-03-25 |
Netkar Therapeutics |
Polymer conjugates of ziconotide peptides
|
WO2010033216A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of nesiritide peptides
|
US20110171160A1
(en)
*
|
2008-09-19 |
2011-07-14 |
Nektar Therapeutics |
Polymer conjugates of kiss1 peptides
|
US20110165112A1
(en)
*
|
2008-09-19 |
2011-07-07 |
Nektar Therapeutics |
Polymer conjugates of c-peptides
|
US20110171165A1
(en)
*
|
2008-09-19 |
2011-07-14 |
Nektar Therapeutics |
Polymer conjugates of opioid growth factor peptides
|
AU2009292643B2
(en)
|
2008-09-19 |
2016-02-18 |
Nektar Therapeutics |
Polymer conjugates of therapeutic peptides
|
WO2010033205A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of v681-like peptides
|
US20110171161A1
(en)
*
|
2008-09-19 |
2011-07-14 |
Nektar Therapeutics |
Polymer conjugates of protegrin peptides
|
US20110171162A1
(en)
*
|
2008-09-19 |
2011-07-14 |
Nektar Therapeutics |
Polymer conjugates of thymosin alpha 1 peptides
|
AU2009292651A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of AOD-like peptides
|
WO2010033218A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of osteocalcin peptides
|
KR20110063457A
(ko)
|
2008-09-23 |
2011-06-10 |
넥타르 테라퓨틱스 |
대상에서의 지속적 치료 약물 농도 달성을 위한 조성물 및 방법
|
NO2337846T3
(de)
|
2008-09-26 |
2018-06-16 |
|
|
NZ592250A
(en)
|
2008-09-26 |
2012-11-30 |
Lilly Co Eli |
Modified animal erythropoietin polypeptides and their uses
|
WO2010039985A1
(en)
|
2008-10-01 |
2010-04-08 |
Quintessence Biosciences, Inc. |
Therapeutic Ribonucleases
|
WO2010048018A1
(en)
*
|
2008-10-21 |
2010-04-29 |
Enzon Pharmaceuticals, Inc. |
Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
|
RS58728B1
(sr)
|
2008-12-09 |
2019-06-28 |
Halozyme Inc |
Produženi rastvorljivi ph20 polipeptidi i njihove upotrebe
|
US8512519B2
(en)
|
2009-04-24 |
2013-08-20 |
Eastman Chemical Company |
Sulfopolyesters for paper strength and process
|
MX2012003282A
(es)
|
2009-09-17 |
2012-04-30 |
Baxter Healthcare Sa |
Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
|
DE102009045969B4
(de)
|
2009-10-23 |
2019-01-31 |
Technische Universität Bergakademie Freiberg |
Verfahren und Mittel zur Spaltung von Estern, Amiden und Thioestern der Ameisensäure
|
AU2010325960C1
(en)
|
2009-12-02 |
2015-08-06 |
Adamas Pharma, Llc |
Amantadine compositions and methods of use
|
CN104017063A
(zh)
|
2009-12-21 |
2014-09-03 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
CN107674121A
(zh)
|
2009-12-21 |
2018-02-09 |
Ambrx 公司 |
经过修饰的牛促生长素多肽和其用途
|
AR079344A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
|
AR079345A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina
|
NZ603399A
(en)
|
2010-05-17 |
2014-09-26 |
Cebix Inc |
Pegylated c-peptide
|
WO2012004007A1
(en)
|
2010-07-09 |
2012-01-12 |
Fresenius Kabi Deutschland Gmbh |
Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
|
US20130217871A1
(en)
|
2010-07-09 |
2013-08-22 |
Helmut Knoller |
Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
|
ES2661089T3
(es)
|
2010-07-20 |
2018-03-27 |
Halozyme Inc. |
Métodos de tratamiento o prevención de los efectos secundarios adversos asociados con la administración de un agente anti-hialuronano
|
WO2012024452A2
(en)
|
2010-08-17 |
2012-02-23 |
Ambrx, Inc. |
Modified relaxin polypeptides and their uses
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
US9012469B2
(en)
|
2010-09-30 |
2015-04-21 |
Astrazeneca Ab |
Crystalline naloxol-peg conjugate
|
US20120183861A1
(en)
|
2010-10-21 |
2012-07-19 |
Eastman Chemical Company |
Sulfopolyester binders
|
WO2012054822A1
(en)
|
2010-10-22 |
2012-04-26 |
Nektar Therapeutics |
Pharmacologically active polymer-glp-1 conjugates
|
TWI557135B
(zh)
|
2010-11-03 |
2016-11-11 |
介控生化科技公司 |
經修飾之第九因子多胜肽及其用途
|
CA2817994C
(en)
*
|
2010-12-01 |
2019-01-22 |
Huntsman Petrochemical Llc |
Sterically hindered amines and associated methods
|
US10894087B2
(en)
|
2010-12-22 |
2021-01-19 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
|
WO2012088422A1
(en)
|
2010-12-22 |
2012-06-28 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of taxane-based compounds
|
JP2014510045A
(ja)
|
2011-02-08 |
2014-04-24 |
ハロザイム インコーポレイテッド |
ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用
|
CN105797140B
(zh)
|
2011-06-17 |
2020-08-11 |
哈洛齐梅公司 |
乙酰透明质酸降解酶的稳定制剂
|
CA2839512C
(en)
|
2011-06-17 |
2018-01-02 |
Halozyme, Inc. |
Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
|
US9993529B2
(en)
|
2011-06-17 |
2018-06-12 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
US20130071394A1
(en)
|
2011-09-16 |
2013-03-21 |
John K. Troyer |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
|
WO2013063155A2
(en)
|
2011-10-24 |
2013-05-02 |
Halozyme, Inc. |
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
|
US8962553B2
(en)
|
2011-11-17 |
2015-02-24 |
Cebix Ab |
Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide
|
AU2012362141B2
(en)
|
2011-12-30 |
2017-09-21 |
Halozyme, Inc. |
PH20 polypeptide variants, formulations and uses thereof
|
US8906200B2
(en)
|
2012-01-31 |
2014-12-09 |
Eastman Chemical Company |
Processes to produce short cut microfibers
|
AU2013243873B2
(en)
|
2012-04-04 |
2016-08-25 |
Halozyme, Inc. |
Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
|
EP3505534A1
(de)
|
2012-06-08 |
2019-07-03 |
Sutro Biopharma, Inc. |
Antikörper mit nichtnatürlichen stellenspezifischen aminosäureresten, verfahren zu deren herstellung und verfahren zu deren verwendung
|
DK2863955T3
(en)
|
2012-06-26 |
2017-01-23 |
Sutro Biopharma Inc |
MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
|
BR112015004022B1
(pt)
|
2012-08-31 |
2023-04-25 |
Sutro Biopharma, Inc |
Aminoácidos modificados compreendendo um grupo azido
|
WO2014062856A1
(en)
|
2012-10-16 |
2014-04-24 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
US9303357B2
(en)
|
2013-04-19 |
2016-04-05 |
Eastman Chemical Company |
Paper and nonwoven articles comprising synthetic microfiber binders
|
US10154971B2
(en)
|
2013-06-17 |
2018-12-18 |
Adamas Pharma, Llc |
Methods of administering amantadine
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ph20玻尿酸酶變異體及其用途
|
ES2658039T3
(es)
|
2013-07-10 |
2018-03-08 |
Sutro Biopharma, Inc. |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
EP3077008B1
(de)
|
2013-12-06 |
2023-10-04 |
Jie Han |
Bioreversible pro-elemente für stickstoffhaltige und hydroxylhaltige arzneimittel
|
US9598802B2
(en)
|
2013-12-17 |
2017-03-21 |
Eastman Chemical Company |
Ultrafiltration process for producing a sulfopolyester concentrate
|
US9605126B2
(en)
|
2013-12-17 |
2017-03-28 |
Eastman Chemical Company |
Ultrafiltration process for the recovery of concentrated sulfopolyester dispersion
|
US10358636B2
(en)
|
2014-05-14 |
2019-07-23 |
Stealth Biologics, Llc |
Deimmunized lysostaphin and methods of use
|
HUE043847T2
(hu)
|
2014-08-28 |
2019-09-30 |
Halozyme Inc |
Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
|
ES2753391T3
(es)
|
2014-10-14 |
2020-04-08 |
Halozyme Inc |
Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
|
UY36370A
(es)
|
2014-10-24 |
2016-04-29 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Polipéptidos fgf-21 modificados y sus usos
|
CA3032692A1
(en)
|
2016-08-09 |
2018-02-15 |
Eli Lilly And Company |
Combination antibody therapy for the treatment of neurodegenerative diseases
|
AU2018219283B2
(en)
|
2017-02-08 |
2022-05-19 |
Bristol-Myers Squibb Company |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
AU2018290281B2
(en)
|
2017-06-22 |
2021-12-16 |
Vertex Pharmaceuticals Incorporated |
Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
|
WO2019063958A1
(en)
|
2017-09-27 |
2019-04-04 |
The University Of York |
BIOCONJUGATION OF POLYPEPTIDES
|
US11491212B1
(en)
|
2017-09-27 |
2022-11-08 |
Catalyst Biosciences, Inc. |
Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
|
WO2019222435A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
US20220056093A1
(en)
|
2018-09-11 |
2022-02-24 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and their uses
|
CN113366015A
(zh)
|
2018-10-19 |
2021-09-07 |
Ambrx公司 |
白细胞介素-10多肽缀合物、其二聚体及其用途
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
KR20210110848A
(ko)
|
2018-12-28 |
2021-09-09 |
카탈리스트 바이오사이언시즈, 인코포레이티드 |
변형된 유로키나제 유형 플라스미노겐 활성제 폴리펩타이드 및 사용 방법
|
US20220226488A1
(en)
|
2019-02-12 |
2022-07-21 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
US11377173B1
(en)
|
2019-07-30 |
2022-07-05 |
Christopher T. Stanton |
Automated cover support and method
|
CN115362168A
(zh)
|
2020-01-14 |
2022-11-18 |
辛德凯因股份有限公司 |
偏向化il2突变蛋白方法和组合物
|
WO2021154414A2
(en)
|
2020-01-29 |
2021-08-05 |
Catalyst Biosciences, Inc. |
Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
|
MX2022011163A
(es)
|
2020-03-11 |
2022-10-18 |
Ambrx Inc |
Conjugados de polipeptidos de interleucina-2 y sus usos.
|
EP3954393A1
(de)
|
2020-08-13 |
2022-02-16 |
Bioasis Technologies Inc. |
Kombinationstherapien zur verabreichung über die blut-hirn-schranke hinweg
|
CA3190606A1
(en)
|
2020-08-20 |
2022-02-24 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
CA3213805A1
(en)
|
2021-04-03 |
2022-10-06 |
Feng Tian |
Anti-her2 antibody-drug conjugates and uses thereof
|